TRAIL-R2 monoclonal antibody therapeutic
Latest Information Update: 16 Jul 2019
At a glance
- Originator Kirin Pharma Company
- Developer Kyowa Kirin
- Class Monoclonal antibodies
- Mechanism of Action TNFRSF10B protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in Canada (Parenteral)
- 01 Oct 2008 Kirin Pharma Company has merged with Kyowa Hakko to form Kyowa Hakko Kirin